INZY — Inozyme Pharma Share News
0.000.00%
Last trade - 00:00- $257.60m
- $219.11m
Inozyme Pharma Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Inozyme Pharma Expects To Initiate A Pivotal Trial In Pediatric Patients With ABCC6 Deficiency In Q1 2025
Brief: Inozyme Pharma Q3 EPS USD -0.29
Brief: Inozyme Pharma Highlights Inclusion Of Generalized Arterial Calcification Of Infancy In Genomics England’S Generation Study Of Rare Conditions
Brief: Inozyme Pharma Reports Second Quarter 2023 Financial Results
U.S. STOCKS ON THE MOVE-US regional banks, Enphase, Centene
U.S. STOCKS ON THE MOVE-Tupperware Brands, Comcast, Centene
U.S. STOCKS ON THE MOVE-Reata, Boston Beer, First Solar
Inozyme Pharma slips on $60 mln stock offering
Brief: Inozyme Pharma Inc Says Public Offering Of 12.5 Million Common Shares Priced At $4.80 Per Share
Brief: Inozyme Pharma, Inc. Announces Proposed Offering Of Common Stock
Brief: Inozyme Pharma Announces Updates On Global Development Strategy Of INZ-701 For Treatment Of ENPP1 Deficiency
Brief: Inozyme Pharma Announces Dosing Of First Infant With Enpp1 Deficiency In A Phase 1B Trial Of Inz-701
Inozyme Pharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: Inozyme Pharma Reports First Quarter 2023 Financial Results And Provides Business Highlights
Inozyme Pharma Inc expected to post a loss of 45 cents a share - Earnings Preview
Inozyme up as co on track to report early-stage data for rare disease therapy
Brief: Inozyme Pharma To Present Recently Announced Preliminary Data From Ongoing Phase 1/2 Trial In Enpp1 Deficiency At Ects
U.S. RESEARCH ROUNDUP- Acuity Brands, Hershey, Phreesia